Navigation Links
IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
Date:12/10/2012

NEW YORK, Dec. 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that Dr. Harry Fisch has joined the Board of Scientific Advisors and will head up the new Urology Department at IntelliCell. 

IntelliCell's Chairman and CEO, Dr. Steven Victor stated, "Our Company is very pleased to announce today that Dr. Fisch is joining our Advisory Board and will be the Director of Urology for IntelliCell.  He is a pioneering surgeon and respected on the national stage for his work on microsurgical techniques.  I am looking forward to working with him as we expand the potential benefits of Regenerative Medicine into the practice of urology."

Said Dr. Fisch, "I believe that the promise of Regenerative Medicine for patients suffering from a number of urological disorders including erectile dysfunction may become an important part in the practice of medicine.  This is an exciting time in medicine and I am looking forward to working with cutting edge technologies like IntelliCell's and improving the clinical outcomes of my patients."   

About IntelliCell BioSciences

IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs.  The Company has several patent-pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells.  The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes.  IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics.  The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center. 

About Dr. Fisch

Dr. Harry Fisch is Clinical Professor of Urology and Reproductive Medicine at Weill-Cornell Medical College/New York Presbyterian Hospital, and is a board-certified urologist and microsurgeon who is also one of the nation's leaders in the diagnosis and treatment of Men's health issues as well as sexuality and fertility problems in couples. Internationally renowned, he has pioneered microsurgical techniques for disorders associated with male infertility such as vasectomy reversal and repair of varicoceles. He has been frequently cited in a variety of publications, including USA Today, The New York Times, and The Washington Post and has appeared on television's 60 Minutes, 20/20, CNN and Today, among many others. He has been named to the "Best Doctors in America" and "New York Magazine Top Doctor" for the past 9 years.

Dr. Fisch has written two engaging and critically acclaimed books on the subject of male reproduction and sexuality.

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email:  rsexauer@intellicellbiosciences.com 
(646) 576-8706  


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
2. IntelliCell BioSciences Expands Management Team
3. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
4. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
5. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
6. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
7. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
8. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , ... February 04, 2016 , ... ... GC-MS and triple quad LC-MS, host live demos and poster sessions, and present ... and exhibition. The conference takes place March 6 to 10 at the Georgia ...
(Date:2/4/2016)... 4, 2016 --> ... company is pleased to provide the following update on recent ... Over the last 3 months we have significantly increased our ... exceeding $1,000,000. As a result, we have positioned ourselves to ... license agreement and expect that development to continue on schedule. ...
(Date:2/4/2016)... Strasbourg, France , to ... Strasbourg, France , to the US company ... pleased to announce that it acted as an advisor to ... Strasbourg, France , to the US company ... --> Transgene (Euronext: TNG), a member of Institut ...
(Date:2/3/2016)... COPENHAGEN, Denmark , Feb. 3, 2016 ... stage biotechnology company that applies its innovative TransCon technology ... to present at an upcoming investor conference.Event:2016 Leerink Partners ... York, NY Date:  , Wednesday, February 10, 2016 Time:  ... --> www.ascendispharma.com . --> An audio ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)... 2016 A market that just keeps on ... the explosion in genomics knowledge. Learn all about it ... range of dynamic trends are pushing market growth and ... - pharmacogenomics - pathogen evolution - next generation sequencing ... greater understanding of the role of genetic material in ...
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
Breaking Biology News(10 mins):